Nicotinic Acid 250mg

Country: Ավստրալիա

language: անգլերեն

source: Department of Health (Therapeutic Goods Administration)

active_ingredient:

nicotinic acid, Quantity: 250 mg

MAH:

Alphapharm Pty Ltd

pharmaceutical_form:

Tablet, uncoated

composition:

Excipient Ingredients: lactose monohydrate; magnesium stearate; maize starch; povidone; purified talc

administration_route:

Oral

units_in_package:

200 tablets, 100 tablets

class:

Medicine Registered

prescription_type:

(S3) Pharmacist Only Medicine

therapeutic_indication:

Nicotinic acid is an essential dietary constituent, the lack of which leads to the clinical condition known as pellagra, which is characterised by loss of appetite, lethargy, weakness, diarrhoea, dermatitis and mental changes. An erythematous eruption resembling sunburn first appears on the back of the hands. Other areas exposed to light are later involved and eventually the lesions may be more widespread. The cutaneous manifestations are characteristically symmetrical and may darken, desquamate and scar. Nicotinic acid has been approved for the treatment of hypercholesterolaemia and hypertriglyceridaemia. It should be used as adjunctive therapy in addition to diet and other measures. Nicotinic acid can also be used to treat Frederickson-Lees Levy hyperlipoproteinaemia type II, IIB, III, IV and V.

leaflet_short:

Visual Identification: White, bevelled edge tablet with breakline on one side; Container Type: Bottle; Container Material: Glass; Container Life Time: 3 Years; Container Temperature: Store below 30 degrees Celsius

authorization_status:

Registered

authorization_date:

1991-10-21